146 related articles for article (PubMed ID: 31770625)
1. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; MacGowan A; Grier S; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Maurer S; Rodriguez-Bano J; Morales I; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Int J Antimicrob Agents; 2020 Feb; 55(2):105847. PubMed ID: 31770625
[TBL] [Abstract][Full Text] [Related]
2. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
[TBL] [Abstract][Full Text] [Related]
3. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
7. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
[TBL] [Abstract][Full Text] [Related]
11. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
14. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.
Rojas A; Palacios-Baena ZR; López-Cortés LE; Rodríguez-Baño J
Clin Microbiol Infect; 2019 Aug; 25(8):964-970. PubMed ID: 30995530
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
17. Morbidity associated with Pseudomonas aeruginosa bloodstream infections.
Scheetz MH; Hoffman M; Bolon MK; Schulert G; Estrellado W; Baraboutis IG; Sriram P; Dinh M; Owens LK; Hauser AR
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):311-9. PubMed ID: 19345039
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study.
Atamna A; Margalit I; Ayada G; Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; Macgowan A; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodríguez-Baño J; de Cueto M; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstei Y; Yahav D;
Infection; 2023 Aug; 51(4):1003-1012. PubMed ID: 36571672
[TBL] [Abstract][Full Text] [Related]
19. Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in Pseudomonas aeruginosa.
Ferreira ML; Dantas RC; Faria ALS; Gonçalves IR; Silveira de Brito C; Queiroz LL; Gontijo-Filho PP; Ribas RM
J Med Microbiol; 2015 Mar; 64(Pt 3):262-271. PubMed ID: 25596115
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
